Cargando…
Analysis of recreational psychedelic substance use experiences classified by substance
RATIONALE AND OBJECTIVES: Differences among psychedelic substances regarding their subjective experiences are clinically and scientifically interesting. Quantitative linguistic analysis is a powerful tool to examine such differences. This study compared five psychedelic substance report groups and a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799548/ https://www.ncbi.nlm.nih.gov/pubmed/35031816 http://dx.doi.org/10.1007/s00213-022-06062-3 |
_version_ | 1784642085761056768 |
---|---|
author | Hase, Adrian Erdmann, Max Limbach, Verena Hasler, Gregor |
author_facet | Hase, Adrian Erdmann, Max Limbach, Verena Hasler, Gregor |
author_sort | Hase, Adrian |
collection | PubMed |
description | RATIONALE AND OBJECTIVES: Differences among psychedelic substances regarding their subjective experiences are clinically and scientifically interesting. Quantitative linguistic analysis is a powerful tool to examine such differences. This study compared five psychedelic substance report groups and a non-psychedelic report group on quantitative linguistic markers of psychological states and processes derived from recreational use-based online experience reports. METHODS: Using 2947 publicly available online reports, we compared Ayahuasca and N,N-dimethyltryptamine (DMT, analyzed together), ketamine, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin (mushroom), and antidepressant drug use experiences. We examined word frequencies related to various psychological states and processes and semantic proximity to psychedelic and mystical experience scales. RESULTS: Linguistic markers of psychological function indicated distinct effect profiles. For example, MDMA experience reports featured an emotionally intensifying profile accompanied by many cognitive process words and dynamic-personal language. In contrast, Ayahuasca and DMT experience reports involved relatively little emotional language, few cognitive process words, increased analytical thinking-associated language, and the most semantic similarity with psychedelic and mystical experience descriptions. LSD, psilocybin mushroom, and ketamine reports showed only small differences on the emotion-, analytical thinking-, psychedelic, and mystical experience-related language outcomes. Antidepressant reports featured more negative emotional and cognitive process-related words, fewer positive emotional and analytical thinking-related words, and were generally not similar to mystical and psychedelic language. CONCLUSION: This article addresses an existing research gap regarding the comparison of different psychedelic drugs on linguistic profiles of psychological states, processes, and experiences. The large sample of experience reports involving multiple psychedelic drugs provides valuable information that would otherwise be difficult to obtain. The results could inform experimental research into psychedelic drug effects in healthy populations and clinical trials for psychedelic treatments of psychiatric problems. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00213-022-06062-3. |
format | Online Article Text |
id | pubmed-8799548 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-87995482022-02-02 Analysis of recreational psychedelic substance use experiences classified by substance Hase, Adrian Erdmann, Max Limbach, Verena Hasler, Gregor Psychopharmacology (Berl) Original Investigation RATIONALE AND OBJECTIVES: Differences among psychedelic substances regarding their subjective experiences are clinically and scientifically interesting. Quantitative linguistic analysis is a powerful tool to examine such differences. This study compared five psychedelic substance report groups and a non-psychedelic report group on quantitative linguistic markers of psychological states and processes derived from recreational use-based online experience reports. METHODS: Using 2947 publicly available online reports, we compared Ayahuasca and N,N-dimethyltryptamine (DMT, analyzed together), ketamine, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin (mushroom), and antidepressant drug use experiences. We examined word frequencies related to various psychological states and processes and semantic proximity to psychedelic and mystical experience scales. RESULTS: Linguistic markers of psychological function indicated distinct effect profiles. For example, MDMA experience reports featured an emotionally intensifying profile accompanied by many cognitive process words and dynamic-personal language. In contrast, Ayahuasca and DMT experience reports involved relatively little emotional language, few cognitive process words, increased analytical thinking-associated language, and the most semantic similarity with psychedelic and mystical experience descriptions. LSD, psilocybin mushroom, and ketamine reports showed only small differences on the emotion-, analytical thinking-, psychedelic, and mystical experience-related language outcomes. Antidepressant reports featured more negative emotional and cognitive process-related words, fewer positive emotional and analytical thinking-related words, and were generally not similar to mystical and psychedelic language. CONCLUSION: This article addresses an existing research gap regarding the comparison of different psychedelic drugs on linguistic profiles of psychological states, processes, and experiences. The large sample of experience reports involving multiple psychedelic drugs provides valuable information that would otherwise be difficult to obtain. The results could inform experimental research into psychedelic drug effects in healthy populations and clinical trials for psychedelic treatments of psychiatric problems. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00213-022-06062-3. Springer Berlin Heidelberg 2022-01-15 2022 /pmc/articles/PMC8799548/ /pubmed/35031816 http://dx.doi.org/10.1007/s00213-022-06062-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Investigation Hase, Adrian Erdmann, Max Limbach, Verena Hasler, Gregor Analysis of recreational psychedelic substance use experiences classified by substance |
title | Analysis of recreational psychedelic substance use experiences classified by substance |
title_full | Analysis of recreational psychedelic substance use experiences classified by substance |
title_fullStr | Analysis of recreational psychedelic substance use experiences classified by substance |
title_full_unstemmed | Analysis of recreational psychedelic substance use experiences classified by substance |
title_short | Analysis of recreational psychedelic substance use experiences classified by substance |
title_sort | analysis of recreational psychedelic substance use experiences classified by substance |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799548/ https://www.ncbi.nlm.nih.gov/pubmed/35031816 http://dx.doi.org/10.1007/s00213-022-06062-3 |
work_keys_str_mv | AT haseadrian analysisofrecreationalpsychedelicsubstanceuseexperiencesclassifiedbysubstance AT erdmannmax analysisofrecreationalpsychedelicsubstanceuseexperiencesclassifiedbysubstance AT limbachverena analysisofrecreationalpsychedelicsubstanceuseexperiencesclassifiedbysubstance AT haslergregor analysisofrecreationalpsychedelicsubstanceuseexperiencesclassifiedbysubstance |